Coronary Artery Disease Polygenic Risk Score Identifies Patients at Higher Risk for Recurrent Cardiovascular Events in the CANTOS Trial
| Autor: | Claudia Hon, Ma’en Obeidat, Jason M. Laramie, Philippe Marc, Pablo Serrano-Fernandez, Paul M. Ridker, Margaret L Healey, Michael T. Beste, Arkady I Gusev, Aviv Madar, Huilei Xu, Nicole Hartmann, Denise Yates, Scott Kennedy, Sergio Kaiser, Eric C. Svensson |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Clinical Trials as Topic
Treatment response medicine.medical_specialty business.industry Coronary Artery Disease General Medicine Antibodies Monoclonal Humanized Atherosclerosis medicine.disease Coronary artery disease Canakinumab Disease severity Risk Factors Internal medicine medicine Humans Polygenic risk score Myocardial infarction business Disease burden Mace medicine.drug |
| Zdroj: | Circulation: Genomic and Precision Medicine. 14 |
| ISSN: | 2574-8300 |
| DOI: | 10.1161/circgen.121.003440 |
| Popis: | No formal abstract in format we plan to submit to journal (a short report). Informally, the work presented here adds to a body of evidence that shows how polygenic risk scores (PRS) for coronary artery disease (CAD) can be used to inform on patient's disease severity, disease progression, and potential for treatment response stratification. Key results include, patients in highest tertile PRS have a higher CAD disease burden at baseline (measured by number of myocardial infractions at trail start), progress faster in CAD (measured by time to first major adverse cardiovascular event, MACE), and may respond better to Canakinumab therapy at the highest dose of 300mg. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|